A C Hesseling1, H B Jaspan2, G F Black3, N Nene3, G Walzl3. 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. 2. Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town Health Sciences Faculty, Cape Town, South Africa; Seattle Children's Research Institute, Seattle, Washington, USA. 3. Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical TB Research/Medical Research Council Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) exposed infants are at high risk of Mycobacterium tuberculosis exposure, have high rates of progression to tuberculosis (TB) disease and are at significant risk of bacille Calmette-Guérin (BCG) induced adverse events. OBJECTIVE: To evaluate a delayed BCG vaccination strategy in HIV-exposed infants. DESIGN: A randomised trial of routine BCG vaccinationgiven at birth compared to 14 weeks of age in HIV-exposed non-infected and non-HIV-exposed infants to investigate longitudinal BCG-induced immune responses using a 7-day whole blood interferon-gamma (IFN-γ) enzyme-linked immunosorbent assay. RESULTS: A significantly higher proportion of infants had positive responses to M. tuberculosis purified protein derivative (PPD) and BCG at 14 weeks in the birth vs. delayed vaccination groups (P = 0.001 for both). This difference was no longer apparent at weeks 24 or 52. Among infants vaccinated at birth, the 14-week IFN-γ response to M. tuberculosis PPD was lower among HIV-exposed than non-exposed infants (276.5 pg/ml vs. 790.2, P = 0.048). Among all infants, there were significant correlations between the magnitude of IFN-γ responses to BCG, M. tuberculosis PPD, TB 10.4 and culture filtrate protein 10/early secreted antigenic target 6. CONCLUSIONS: The timing of vaccination had limited effect on BCG-induced IFN-γ responses, which waned considerably over 1 year despite initial vigorous responses in both vaccination groups. The lower responses in HIV-exposed non-infected infants suggest potentially altered mycobacterial immunity early in life.
RCT Entities:
BACKGROUND:Human immunodeficiency virus (HIV) exposed infants are at high risk of Mycobacterium tuberculosis exposure, have high rates of progression to tuberculosis (TB) disease and are at significant risk of bacille Calmette-Guérin (BCG) induced adverse events. OBJECTIVE: To evaluate a delayed BCG vaccination strategy in HIV-exposed infants. DESIGN: A randomised trial of routine BCG vaccination given at birth compared to 14 weeks of age in HIV-exposed non-infected and non-HIV-exposed infants to investigate longitudinal BCG-induced immune responses using a 7-day whole blood interferon-gamma (IFN-γ) enzyme-linked immunosorbent assay. RESULTS: A significantly higher proportion of infants had positive responses to M. tuberculosis purified protein derivative (PPD) and BCG at 14 weeks in the birth vs. delayed vaccination groups (P = 0.001 for both). This difference was no longer apparent at weeks 24 or 52. Among infants vaccinated at birth, the 14-week IFN-γ response to M. tuberculosis PPD was lower among HIV-exposed than non-exposed infants (276.5 pg/ml vs. 790.2, P = 0.048). Among all infants, there were significant correlations between the magnitude of IFN-γ responses to BCG, M. tuberculosis PPD, TB 10.4 and culture filtrate protein 10/early secreted antigenic target 6. CONCLUSIONS: The timing of vaccination had limited effect on BCG-induced IFN-γ responses, which waned considerably over 1 year despite initial vigorous responses in both vaccination groups. The lower responses in HIV-exposed non-infected infants suggest potentially altered mycobacterial immunity early in life.
Authors: Nazma Mansoor; Brian Abel; Thomas J Scriba; Jane Hughes; Marwou de Kock; Michele Tameris; Sylvia Mlenjeni; Lea Denation; Francesca Little; Sebastian Gelderbloem; Anthony Hawkridge; W Henry Boom; Gilla Kaplan; Gregory D Hussey; Willem A Hanekom Journal: Clin Immunol Date: 2008-11-08 Impact factor: 3.969
Authors: Benjamin M N Kagina; Brian Abel; Mark Bowmaker; Thomas J Scriba; Sebastian Gelderbloem; Erica Smit; Mzwandile Erasmus; Nonhlanhla Nene; Gerhard Walzl; Gillian Black; Gregory D Hussey; Anneke C Hesseling; Willem A Hanekom Journal: Vaccine Date: 2009-07-17 Impact factor: 3.641
Authors: Jayne S Sutherland; Ifedayo M Adetifa; Philip C Hill; Richard A Adegbola; Martin O C Ota Journal: Eur J Immunol Date: 2009-03 Impact factor: 5.532
Authors: A C Hesseling; L F Johnson; H Jaspan; M F Cotton; A Whitelaw; H S Schaaf; P E M Fine; B S Eley; B J Marais; J Nuttall; N Beyers; P Godfrey-Faussett Journal: Bull World Health Organ Date: 2009-07 Impact factor: 9.408
Authors: Maeve K Lalor; Anne Ben-Smith; Patricia Gorak-Stolinska; Rosemary E Weir; Sian Floyd; Rose Blitz; Hazzie Mvula; Melanie J Newport; Keith Branson; Nuala McGrath; Amelia C Crampin; Paul E M Fine; Hazel M Dockrell Journal: J Infect Dis Date: 2009-03-15 Impact factor: 5.226
Authors: A C Hesseling; J Caldwell; M F Cotton; B S Eley; H B Jaspan; K Jennings; B J Marais; J Nuttall; H Rabie; P Roux; H S Schaaf Journal: S Afr Med J Date: 2009-02
Authors: Emily K Forbes; Clare Sander; Edward O Ronan; Helen McShane; Adrian V S Hill; Peter C L Beverley; Elma Z Tchilian Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Sarah Burl; Uche J Adetifa; Momodou Cox; Ebrima Touray; Martin O Ota; Arnaud Marchant; Hilton Whittle; Helen McShane; Sarah L Rowland-Jones; Katie L Flanagan Journal: J Immunol Date: 2010-07-19 Impact factor: 5.422
Authors: Rosemary E Weir; Patricia Gorak-Stolinska; Sian Floyd; Maeve K Lalor; Sally Stenson; Keith Branson; Rose Blitz; Anne Ben-Smith; Paul E M Fine; Hazel M Dockrell Journal: BMC Infect Dis Date: 2008-01-25 Impact factor: 3.090
Authors: Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam Journal: JCI Insight Date: 2019-12-19
Authors: Christina Balle; Blair Armistead; Agano Kiravu; Xiaochang Song; Anna-Ursula Happel; Angela A Hoffmann; Sami B Kanaan; J Lee Nelson; Clive M Gray; Heather B Jaspan; Whitney E Harrington Journal: J Clin Invest Date: 2022-07-01 Impact factor: 19.456
Authors: Chloe I Jones; Suzanne L Rose; Ashley Shutt; Cristiana Cairo; Natasha M Bourgeois; Manhattan Charurat; Donald L Sodora; Matthew P Wood Journal: AIDS Date: 2021-01-01 Impact factor: 4.632
Authors: Elisa Nemes; Anneke C Hesseling; Michele Tameris; Katya Mauff; Katrina Downing; Humphrey Mulenga; Penelope Rose; Marieke van der Zalm; Sharon Mbaba; Danelle Van As; Willem A Hanekom; Gerhard Walzl; Thomas J Scriba; Helen McShane; Mark Hatherill Journal: Clin Infect Dis Date: 2018-02-01 Impact factor: 9.079